deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03581942

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Interventions Copanlisib Ibrutinib
Updated 21 times since 2018 Last updated: Feb 5, 2026 Started: Aug 23, 2018 Primary completion: Feb 5, 2026 Completion: Feb 5, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03581942, this PHASE1/PHASE2 trial focuses on Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 21 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~May 2020 · 11 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

21 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Oct 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 16 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Aug 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2022 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jun 2019 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations